Stiripentol in Dravet Syndrome: Growth, Cognitive Development and Long-Term Follow-Up Management

　　Stiripentol is commonly used as adjunctive therapy for Dravet syndrome.Some pediatric patients experience reduced appetite and slowed weight gain during treatment.Because frequent seizures and feeding difficulties inherent to Dravet syndrome can also impair growth,it is difficult to attribute growth changes solely to the medication.Current data suggest a relatively limited impact on height,while slowed weight gain is more frequently observed.

　　It is recommended to measure height and weight every 3 months and plot growth curves against age-matched references.If two consecutive visits show a marked decline in height velocity,clinicians should evaluate nutritional intake,thyroid function,seizure control and drug dosage.

　　Evidence for direct cognitive impairment caused by stiripentol remains limited.Long-term intellectual outcomes mainly depend on seizure control,the frequency of status epilepticus and genetic background.Effective seizure control usually brings greater developmental benefits than the potential risks of the drug.Developmental assessments should use consistent scales and evaluators to enable reliable longitudinal comparison,with referral to pediatric care services when needed.

　　Dose modifications require careful risk-benefit assessment.Increased seizure frequency after dose reduction may adversely affect cognitive and motor development.Decisions should not be based solely on concerns about drug-related growth effects,but on seizure diaries,growth curves and developmental evaluations.

　　Long-term users need attention to bone metabolism and nutrition.Adequate vitamin D and calcium intake should be ensured,with testing of serum calcium,alkaline phosphatase and bone mineral density when indicated.For children with poor appetite,small frequent meals and energy-dense foods can help improve nutritional intake.

　　Stiripentol dosing is weight-based.During periods of rapid growth,recalculation of the dose is required to avoid under-or overexposure.Any dose adjustment must be made by a pediatric neurologist.

　　Recommended assessment schedule:baseline evaluation before treatment,followed by assessments at 3 and 6 months,then every 6 months thereafter.For school-age children,attention and learning performance should be monitored,and formal developmental testing performed as needed.All results should be documented in medical records for multidisciplinary sharing among pediatrics,neurology and rehabilitation teams.

　　Parents are advised to keep daily records of food intake,weight changes,seizure types and frequency,sleep and behavioral or emotional changes.Such continuous home records often reflect long-term trends better than isolated laboratory tests and support clinical decision-making during follow-up visits.

　　The overall benefit-risk profile needs ongoing reassessment.The primary goal in Dravet syndrome is to reduce convulsive seizures and status epilepticus.Maintenance therapy is generally favored when seizures are well controlled and growth remains within an acceptable range.If significant growth retardation emerges,treatment adjustment should be considered after thorough discussion between clinicians and families.